Bright Minds Begins Phase 1 Clinical Trials Focused On Treating Dravet Syndrome
Phase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead product, referred to as BMB-101.
Read more
Bright Minds Biosciences
Bright Minds Biosciences Looks To Raise $4.0 Million Via Overnight Offering
After several days of intense volatility, Bright Minds Biosciences (CSE: DRUG) is looking to capitalize on the sudden investor interest.
Read more
Bright Minds Moves Into Clinical Development Stage Following Positive Toxicity Results
Drug development continues for the Bright Minds Biosciences (CSE: DRUG) lead product. The firm this morning published positive results from
Read more
Bright Minds Bioscience: A Deep Dive
Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright
Read more
Bright Minds Bioscience Approved For Nasdaq Listing
There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE: DRUG) this morning announced that
Read more
Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022
Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing
Read more
Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm
Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer
Read more
Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive
On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising
Read more
Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies
Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The
Read more
Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive
Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom is VP of Discovery at
Read more